BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38104002)

  • 1. Descriptive analysis of prostate cancer pathology data from diagnosis and surgery in men from the 45 and Up Study.
    Gallagher BDT; Chiam K; Bang A; Patel MI; Kench JG; Edwards S; Nair-Shalliker V; Smith DP
    Pathology; 2024 Feb; 56(1):39-46. PubMed ID: 38104002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-related hospitalisations and 'unknown' stage prostate cancer: a population-based record linkage study.
    Luo Q; Yu XQ; Smith DP; Goldsbury DE; Cooke-Yarborough C; Patel MI; O'Connell DL
    BMJ Open; 2017 Jan; 7(1):e014259. PubMed ID: 28077413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    Lawrance S; Bui C; Mahindra V; Arcorace M; Cooke-Yarborough C
    BMC Cancer; 2019 Aug; 19(1):850. PubMed ID: 31462255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed breast cancer pathology data for large-scale studies - access and completeness in NSW, Australia.
    Bartlett MJ; Beral V; Dolja-Gore X; Gathani T; Liu B
    Public Health Res Pract; 2021 Dec; 31(5):. PubMed ID: 34873616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
    McGinley KF; Sun X; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    Int J Urol; 2017 Aug; 24(8):611-617. PubMed ID: 28589550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    Audenet F; Vertosick EA; Fine SW; Sjoberg DD; Vickers AJ; Reuter VE; Eastham JA; Scardino PT; Touijer KA
    J Urol; 2018 Apr; 199(4):961-968. PubMed ID: 29030317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.
    Anderson BB; Oberlin DT; Razmaria AA; Choy B; Zagaja GP; Shalhav AL; Meeks JJ; Yang XJ; Paner GP; Eggener SE
    Eur Urol; 2017 Sep; 72(3):455-460. PubMed ID: 27986368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance.
    Hassan O; Han M; Zhou A; Paulk A; Sun Y; Al-Harbi A; Alrajjal A; Baptista Dos Santos F; Epstein JI
    J Urol; 2018 Jun; 199(6):1482-1487. PubMed ID: 29154905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
    J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment.
    Falzarano SM; Nyame YA; McKenney JK; Przybycin CG; Li J; Stephenson A; Fergany A; Zhou M; Klein EA; Magi-Galluzzi C
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):435-440. PubMed ID: 31900431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study.
    Kristiansen A; Drevin L; Delahunt B; Samaratunga H; Robinson D; Franck Lissbrant I; Stattin P; Egevad L
    Pathology; 2017 Dec; 49(7):715-720. PubMed ID: 29037803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
    Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
    Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
    Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
    BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
    Faisal FA; Tosoian JJ; Han M; Macura KJ; Pavlovich CP; Lotan TL
    J Urol; 2019 May; 201(5):937-942. PubMed ID: 30414957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the cut-off values of tumor diameter, degree of extraprostatic extension, and extent of surgical margin positivity with regard to biochemical recurrence of prostate cancer after radical prostatectomy.
    Kir G; Arikan EA; Seneldir H; Ankarali H; Oznergiz S; Olgun ZC; Yildirim A
    Ann Diagn Pathol; 2020 Feb; 44():151431. PubMed ID: 31837592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens.
    Eastham JA; Kattan MW; Riedel E; Begg CB; Wheeler TM; Gerigk C; Gonen M; Reuter V; Scardino PT
    J Urol; 2003 Dec; 170(6 Pt 1):2292-5. PubMed ID: 14634399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men.
    Samaratunga H; Delahunt B; Yaxley J; Perry-Keene J; Lamb DS; Srigley JR; Egevad L; Nacey JN
    Pathology; 2014 Jan; 46(1):11-4. PubMed ID: 24300729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.